Skip to main content
Premium Trial:

Request an Annual Quote

Grail Partners With Premier's PINC AI to Improve Patient Access to Blood-Based Multi-Cancer Test

NEW YORK – Grail announced on Monday a collaboration with PINC AI, the technology and services platform of healthcare group purchasing organization Premier, to help identify patients who may benefit from early cancer detection using Galleri, Grail's multi-cancer early detection blood test.

PINC AI plans to augment its artificial intelligence-enabled clinical decision support platform to alert doctors to patients with higher risks of cancer who may benefit from early testing using Galleri. This alert will be integrated into the platform's workflow and will be compatible with existing electronic medical health record systems.

The collaborators plan to test their alert system first with Indianapolis-based Community Health Network.

Grail launched Galleri last year in conjunction with the American Society of Clinical Oncology's virtual annual meeting. It is designed to complement existing single-cancer screening tests.

"Galleri is a validated and transformational test that can detect more than 50 cancers with a single blood draw and predict the origin with a high degree of accuracy and a low rate of false positives," Patrick McGill, executive vice president and chief transformation officer at Community Health Network, said in a statement.

"With this collaboration between PINC AI and Grail," he added, "our clinicians will be alerted when patients meet certain criteria for the ordering of a Galleri test. We believe this will make Community Health Network much more effective in our efforts to detect cancers early, when treatments are more effective, giving our patients the best chances of a successful outcome."